Tevogen Bio Holdings (TVGN) said Tuesday it's artificial intelligence initiative Tevogen.AI has launched a partnership with Microsoft (MSFT) to investigate potential treatments for human papilloma virus.
Tevogen said it has developed a dataset of proteins from the HPV genome and is identifying cytotoxic T-cell targets to choose for a trial for TVGN 920, which will be its first oncology product.
"By leveraging Microsoft's cutting-edge AI and cloud technologies, we're able to accelerate our target identification and pre-clinical processes in ways that weren't previously possible," said Tevogen.AI Chief Information Officer and Head Mittul Mehta.
Financial details about the project weren't provided.
Price: 1.91, Change: -0.05, Percent Change: -2.81
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。